Core Viewpoint - The approval of SYH2069 injection by the National Medical Products Administration of China marks a significant milestone for the company, as it is set to be the first GLP-1/GIP receptor dual agonist to enter clinical trials in China, following its prior approval by the FDA for trials in the United States [1][1]. Group 1: Product Development - SYH2069 injection is designed to selectively activate the cAMP pathway, significantly reducing b-arrestin recruitment, which in turn minimizes receptor internalization and desensitization, enhancing drug efficacy and duration of effect [1][1]. - The product incorporates a long half-life modification platform technology, enabling deeper and more sustained weight loss effects compared to existing products [1][1]. Group 2: Clinical Research Findings - In studies involving diet-induced obesity (DIO) mice and non-human primates, SYH2069 demonstrated significantly superior weight loss and metabolic improvement effects compared to similar marketed products [1][1]. - Toxicology studies in non-human primates indicated good tolerability of the product, with no observed vomiting or gastrointestinal adverse reactions [1][1]. Group 3: Clinical Application and Potential - The approved clinical indication for SYH2069 is weight management in individuals who are overweight or obese with at least one weight-related comorbidity [1][1]. - The product also shows potential for improving blood glucose control in adults with type 2 diabetes mellitus (T2DM), indicating high clinical development value [1][1].
石药集团(01093.HK)：GLP-1/GIP受体双偏向性激动多肽注射液(SYH2069注射液)在中国获临床试验批准